Ultragenyx Pharmaceutical (RARE) Enterprise Value (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Enterprise Value of -$406.0 million for Q1 2026, up 16.7% year-over-year from -$347.9 million in Q1 2025, and up 39.67% on a QoQ basis from -$673.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of Enterprise Value data on file, last reported at -$406.0 million in Q1 2026.
- Quarterly Enterprise Value rose 16.7% year-over-year to -$406.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$406.0 million (up 16.7% YoY) and the FY2025 annual result came in at -$673.0 million, down 11.61% from the prior year.
- Enterprise Value rose to -$406.0 million in Q1 2026 per RARE's latest filing, from -$673.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$406.0 million in Q1 2026 and bottomed at -$888.7 million in Q3 2022.
- The 5-year median for Enterprise Value is -$577.6 million (2023), against an average of -$578.7 million.
- The widest annual swing landed in 2023, when Enterprise Value soared 50.25%; it then plunged 39.02% in 2024.
- Tracing RARE's Enterprise Value over 5 years: stood at -$747.8 million in 2022, then rose by 22.75% to -$577.6 million in 2023, then retreated by 4.39% to -$603.0 million in 2024, then declined by 11.61% to -$673.0 million in 2025, then surged by 39.67% to -$406.0 million in 2026.
- Per Business Quant, the three latest RARE Enterprise Value figures stand at -$406.0 million (Q1 2026), -$673.0 million (Q4 2025), and -$418.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -406.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -406.00 Mn |
| Dec 31, 2025 | -673.00 Mn |
| Sep 30, 2025 | -418.25 Mn |
| Jun 30, 2025 | -480.59 Mn |
| Mar 31, 2025 | -487.39 Mn |
| Dec 31, 2024 | -603.00 Mn |
| Sep 30, 2024 | -614.61 Mn |
| Jun 30, 2024 | -763.82 Mn |
| Mar 31, 2024 | -412.08 Mn |
| Dec 31, 2023 | -577.63 Mn |
| Sep 30, 2023 | -442.09 Mn |
| Jun 30, 2023 | -551.98 Mn |
| Mar 31, 2023 | -629.35 Mn |
| Dec 31, 2022 | -747.76 Mn |
| Sep 30, 2022 | -888.68 Mn |
| Jun 30, 2022 | -542.80 Mn |
| Mar 31, 2022 | -598.32 Mn |
| Dec 31, 2021 | -740.20 Mn |
| Sep 30, 2021 | -737.12 Mn |
| Jun 30, 2021 | -845.76 Mn |
| Mar 31, 2021 | -965.41 Mn |
| Dec 31, 2020 | -1.20 Bn |
| Sep 30, 2020 | -765.52 Mn |
| Jun 30, 2020 | -335.64 Mn |
| Mar 31, 2020 | -663.28 Mn |
| Dec 31, 2019 | -755.23 Mn |
| Sep 30, 2019 | -527.06 Mn |
| Jun 30, 2019 | -618.29 Mn |
| Mar 31, 2019 | -715.32 Mn |
| Dec 31, 2018 | -459.71 Mn |
| Sep 30, 2018 | -503.10 Mn |
| Jun 30, 2018 | -547.13 Mn |
| Mar 31, 2018 | -541.35 Mn |
| Dec 31, 2017 | -234.49 Mn |
| Sep 30, 2017 | -371.07 Mn |
| Jun 30, 2017 | -399.65 Mn |
| Mar 31, 2017 | -425.19 Mn |
| Dec 31, 2016 | -380.15 Mn |
| Sep 30, 2016 | -396.43 Mn |
| Jun 30, 2016 | -391.80 Mn |
| Mar 31, 2016 | -411.86 Mn |
| Dec 31, 2015 | -437.00 Mn |
| Sep 30, 2015 | -448.38 Mn |
| Jun 30, 2015 | -326.03 Mn |
| Mar 31, 2015 | -342.57 Mn |
| Dec 31, 2014 | -187.49 Mn |
| Sep 30, 2014 | -201.19 Mn |
| Jun 30, 2014 | -153.27 Mn |
| Mar 31, 2014 | -165.40 Mn |
| Dec 31, 2013 | -2.38 Mn |
| Sep 30, 2013 | -6.05 Mn |
| Jun 30, 2013 | -13.51 Mn |
| Mar 31, 2013 | -64.80 Mn |